Isolated or recombinant Eph A5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.

Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.

Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

Regulatory T cells (Treg) are engineered to express a chimeric antigen receptor (CAR), that specifically binds to a non-endogenous antigenic moiety; and are administered in combination with an effective dose of targeting antibodies, which antibodies (i) bind to an antigen localized at a site of inflammation and (ii) are labeled with the antigenic moiety, wherein inflammation is decreased at the targeted site.

Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.

The present invention relates to an antibody against a PDGF receptor, an antibody-drug conjugate in which a chemotherapeutic agent is conjugated to the antibody against PDGF receptor, and a use of prevention or treatment of ocular neovascular diseases.

The present invention relates to a process for the preparation of a conjugate, comprising a biological molecule, an enzymatic tag, a hydrophilic spacer, a linker and a lipophilic moiety using enzymatic coupling.

The present disclosure provides methods of using a tumor-independent antigen in immunotherapies. The present disclosure provides methods of using a tumor-independent antigen in adoptive cell therapy.

The present disclosure relates to compositions and methods for regulating the immune system and for treating cancers and other immune disorders.